Ideaya Biosciences gains on mid-stage data for eye cancer drug

Shares of California-based drug developer Ideaya Biosciences IDYA.O rise 12% to $30.42 premarket

Company says its experimental drug, darovasertib, showed effectiveness in reducing the size of eye tumors before radiation therapy, in patients with a type of rare eye cancer called neoadjuvant uveal melanoma, in a mid-stage trial

IDYA says its drug also reduced long-term risk of blindness for patients after treatment

The drug received FDA's breakthrough therapy tag in March 2025

Up to last close, stock was up 5.7% YTD